Mylan, Others Hit With Class Action Over Painkillers
Despite significant evidence dating back to the 1970s highlighting the inefficacy and risk of cardiac side effects associated with the drugs' active ingredient propoxyphene, the defendants failed to thoroughly investigate these claims and continued marketing their products as safe and effective for use, the three named plaintiffs allege in...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login